{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "Grohskopf_et_al.__2023_",
  "verification_stats": {
    "total_extracted": 2,
    "verified": 0,
    "rejected": 2,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": 1,
      "quote": "Children were randomized n a 2:1 ratio to receive either Flu cel vax Quad rival ent (0.5 mL/dose containing 15 \u00b5g HA per virus for all ages) or aicensed comparator egg based IIV4 (0.25 mL/dose containing 7.5 \u00b5g HA per virus for those aged 6 through 35 months and 0.5 mL/dose containing 15 \u00b5g HA per virus for those aged 36 through 47 months) (130).",
      "reason": "does not support claim",
      "original_explanation": "This quote describes a pivotal trial for Flu cel vax Quadrivalent, not Flublok, and the comparator is an egg-based IIV4, not Fluarix. It does not support the claim about Flublok versus Fluarix."
    },
    {
      "id": 2,
      "quote": "One recombinant influenza vaccine, Flublok Quad rival ent (RIV4), is expected to be available during the 2022 23 influenza season. RIV4 is approved for persons aged \u226518 years. This vaccine contains recombinant HA produced in an insect cell line using genetic sequences from cell derived influenza viruses and is manufactured without the use of influenza viruses or eggs (127).",
      "reason": "does not support claim",
      "original_explanation": "This quote describes Flublok Quadrivalent but does not mention any pivotal trial or comparison to Fluarix or any other standard-dose vaccine. It does not support the claim."
    }
  ],
  "model_used": "gpt-4.1"
}